These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23242463)

  • 21. Quality of platelet concentrates derived by platelet rich plasma, buffy coat and Apheresis.
    Vasconcelos E; Figueiredo AC; Seghatchian J
    Transfus Apher Sci; 2003 Aug; 29(1):13-6. PubMed ID: 12877887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elimination and multiplication of bacteria during preparation and storage of buffy coat-derived platelet concentrates.
    Mohr H; Bayer A; Gravemann U; Müller TH
    Transfusion; 2006 Jun; 46(6):949-55. PubMed ID: 16734811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relative safety of pooled whole-blood-derived platelets prepared by the buffy-coat method versus single-donor (apheresis) platelets.
    Vamvakas EC
    Clin Lab; 2010; 56(7-8):263-79. PubMed ID: 20857891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The 'cherry buffy-coat syndrome', a cause of decreased platelet yield in platelet concentrates obtained from buffy-coats.
    Rebulla P; Smacchia C; Greppi N; Porretti L; Lopa R; Cernuschi M; Sirchia G
    Vox Sang; 2001 Jan; 80(1):57-60. PubMed ID: 11339070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. International forum: Europe. Buffy-coat-derived platelet concentrates: Swedish experience.
    Högman CF; Berséus O; Eriksson L; Gulliksson H
    Transfus Sci; 1997 Mar; 18(1):3-13. PubMed ID: 10174288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic Effect of Apheresis and Buffy Coat-Derived Platelet Concentrates.
    Zimmermann R
    Clin Lab; 2024 Aug; 70(8):. PubMed ID: 39193973
    [No Abstract]   [Full Text] [Related]  

  • 27. Buffy coat pooled platelet concentrate: A new age platelet component.
    Kumar R; Dhawan HK; Sharma RR; Kaur J
    Asian J Transfus Sci; 2021; 15(2):125-132. PubMed ID: 34908742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro variables of buffy coat-derived platelet concentrates with residual plasma of down to 10% are stably maintained in new-generation platelet additive solutions.
    Gravemann U; Volgmann T; Min K; Philipp R; Lambrecht B; Müller TH; Seltsam A
    Transfusion; 2015 Jul; 55(7):1700-9. PubMed ID: 25677807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Quality of thrombocyte preparations from buffy coat or platelet-rich plasma].
    Bux J; Müller K; Misterek J; Mueller-Eckhardt C
    Beitr Infusionsther; 1990; 26():99-102. PubMed ID: 1703912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality assessment of the preparation and storage of leukocyte-depleted pooled platelet concentrates.
    Chen F; Dai X; Li A; Zheng Y; Hu W
    Hematology; 2024 Dec; 29(1):2293492. PubMed ID: 38193467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Risk Assessment of Single-Donor (Apheresis) Platelet Concentrates and Pooled Whole-Blood-Derived Platelet Concentrates].
    Hitzler W; Hutschenreuter G; Wartensleben H;
    Clin Lab; 2015; 61(7):869-75. PubMed ID: 26299092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathogen-reduced platelets for the prevention of bleeding.
    Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
    Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Technical aspects of buffy coat removal from whole blood and those of platelet production from single buffy coat units.
    Rácz Z; Baróti C
    Biomed Tech (Berl); 1993 Nov; 38(11):266-9. PubMed ID: 8123765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in levels of platelet-derived microparticles in platelet components prepared using the platelet rich plasma, buffy coat, and apheresis procedures.
    Noulsri E; Udomwinijsilp P; Lerdwana S; Chongkolwatana V; Permpikul P
    Transfus Apher Sci; 2017 Apr; 56(2):135-140. PubMed ID: 28029568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of three commercially available buffy coat pooling sets for the preparation of platelet concentrates.
    Feys HB; Devloo R; Sabot B; Coene J; Compernolle V
    Vox Sang; 2018 May; ():. PubMed ID: 29797720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Therapeutic Effect of Apheresis Platelets and Buffy Coat-Derived Platelet Concentrates.
    Wang Z; Chen X; Zhang Y; Lu H; Ren L
    Clin Lab; 2024 Aug; 70(8):. PubMed ID: 39193950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of processing characteristics of photochemically treated pooled platelets: target requirements for the INTERCEPT Blood System comply with routine use after process optimization.
    Picker SM; Speer R; Gathof BS
    Transfus Med; 2004 Jun; 14(3):217-23. PubMed ID: 15180813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolomic analysis of platelets during storage: a comparison between apheresis- and buffy coat-derived platelet concentrates.
    Paglia G; Sigurjónsson ÓE; Rolfsson Ó; Hansen MB; Brynjólfsson S; Gudmundsson S; Palsson BO
    Transfusion; 2015 Feb; 55(2):301-13. PubMed ID: 25156572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?
    Schrezenmeier H; Seifried E
    Vox Sang; 2010 Jul; 99(1):1-15. PubMed ID: 20059760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Storage of platelet concentrates from overnight-stored blood and overnight-stored buffy coat: in vitro studies.
    Rácz Z; Baróti C
    Vox Sang; 1995; 68(3):160-3. PubMed ID: 7625072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.